You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,421,166


✉ Email this page to a colleague

« Back to Dashboard


Title:Pulmonary delivery of aminoglycoside
Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.
Inventor(s): Tarara; Thomas E (Burlinggame, CA), Weers; Jeffry G (Belmont, CA), Venthoye; Maria Geraldine (Foster City, CA)
Assignee: Novartis AG (Basel, CH)
Filing Date:Apr 08, 2014
Application Number:14/247,546
Claims:1. A respirable unit dose of a dispersible powder composition, the composition comprising particles comprising an aminoglycoside and a phospholipid for delivery to the lungs by inhalation, wherein the particles have a geometric diameter of less than 5 microns, wherein the respirable unit dose comprises a fill mass of between 25 and 50 mg and said fill mass comprises between about 14-35 mg of aminoglycoside or salt thereof.

2. A respirable unit dose according to claim 1 wherein the composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses.

3. A respirable unit dose according to claim 1 wherein the composition comprises from about 50% to about 99% by weight aminoglycoside.

4. A respirable unit dose according to claim 1 wherein the particles further comprise calcium chloride.

5. A respirable unit dose according to claim 1 wherein the respirable unit dose is provided in a capsule, the capsule comprising hydroxypropylmethylcellulose.

6. A respirable unit dose according to claim 1 wherein the particles have a bulk density of between 0.08 and 0.20 g/cm.sup.3.

7. A respirable unit dose according to claim 1 wherein the particles have a mass median aerodynamic diameter less than 5 microns.

8. A respirable unit dose according to claim 1 wherein the composition has a pH of between 7 and 10.

9. A respirable unit dose according to claim 1 wherein the respirable unit dose comprises a volume equivalent to a size #00 capsule or smaller capsule size.

10. A respirable unit dose according to claim 1 wherein the respirable unit dose comprises a volume equivalent to a size #2 capsule or smaller capsule size.

11. A respirable unit dose according to claim 1 wherein the aminoglycoside comprises one or more of gentamicin, netilmicin, paramecin, tobramycin, amikacin, kanamycin, neomycin, and streptomycin.

12. A respirable unit dose according to claim 1 wherein the aminoglycoside comprises tobramycin or salt thereof.

13. A respirable unit dose according to claim 1 wherein the particles are spray dried particles.

14. A respirable unit dose according to claim 1 wherein the particles have a moisture content of less than 15% by weight.

15. A respirable unit dose according to claim 1 wherein the particles are hollow and/or porous.

16. A respirable unit dose according to claim 1 wherein each respirable unit dose comprises an emitted dose greater than 70%.

17. A method for administering a composition, the method comprising administering by inhalation less than 6 respirable unit doses according to claim 1 to provide at least 27.6 mg of aminoglycoside to the lungs.

18. A method for treating cystic fibrosis, the method comprising administering a pharmacologically effective amount of aminoglycoside comprising tobramycin to the lungs from a respirable unit dose according to claim 1.

19. A method for administering aminoglycoside to reduce the potential for development of bacteria in the lungs, the method comprising administering a pharmacologically effective amount of aminoglycoside to the lungs from a respirable unit dose according to claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.